Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05310084
Registration number
NCT05310084
Ethics application status
Date submitted
25/03/2022
Date registered
4/04/2022
Date last updated
24/11/2023
Titles & IDs
Public title
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
Query!
Scientific title
A PHASE 3, RANDOMIZED, OBSERVER-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF BNT162b2 WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE (SIIV) IN ADULTS 18 THROUGH 64 YEARS OF AGE
Query!
Secondary ID [1]
0
0
C4591030
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
SARS-CoV-2 Infection
0
0
Query!
COVID-19
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - BNT162b2
Other interventions - Placebo
Other interventions - Seasonal Inactivated Influenza Vaccine
Experimental: Coadministration Group - BNT162b2 and SIIV followed by placebo a month later
Experimental: Separate Administration Group - Placebo and SIIV followed by BNT162b2 a month later
Other interventions: BNT162b2
Intramuscular injection
Other interventions: Placebo
Saline intramuscular injection
Other interventions: Seasonal Inactivated Influenza Vaccine
SIIV intramuscular injection
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Query!
Assessment method [1]
0
0
Local reactions included redness, swelling, and pain at the injection site occurring at the BNT162b2 or placebo injection site. Local reactions were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (>) 2.0 to 5.0 cm, moderate: >5.0 to 10.0 cm, severe: >10.0 cm, and potentially life threatening (Grade 4): necrosis or exfoliative dermatitis. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity, and potentially life threatening (Grade 4): emergency room visit or hospitalization for severe pain. Exact 2-sided confidence interval (CI), based on the Clopper and Pearson method was used.
Query!
Timepoint [1]
0
0
Within 7 Days After Vaccination 1
Query!
Primary outcome [2]
0
0
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Query!
Assessment method [2]
0
0
Local reactions included redness, swelling, and pain at the injection site occurring at the BNT162b2 or placebo injection site. Local reactions were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: greater than >2.0 to 5.0 cm, moderate: >5.0 to 10.0 cm, severe: >10.0 cm, and potentially life threatening (Grade 4): necrosis or exfoliative dermatitis. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity, and potentially life threatening (Grade 4): emergency room visit or hospitalization for severe pain. Exact 2-sided CI, based on the Clopper and Pearson method was used.
Query!
Timepoint [2]
0
0
Within 7 Days After Vaccination 2
Query!
Primary outcome [3]
0
0
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Query!
Assessment method [3]
0
0
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain recorded by participants in an e-diary. Fever was defined as temperature: >=38.0 degrees (deg) Celsius (C), and categorized as: >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C, and >40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity, and severe: prevented daily routine activity. Vomiting graded as mild: 1 to 2 times in 24 hours(h), moderate: >2 times in 24h, severe: required intravenous hydration, and grade 4: emergency room (ER) visit or hospitalization for hypotensive shock. Diarrhea graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h, severe: 6 or more loose stools in 24h, and grade 4: ER visit or hospitalization for severe diarrhea.
Query!
Timepoint [3]
0
0
Within 7 Days After Vaccination 1
Query!
Primary outcome [4]
0
0
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Query!
Assessment method [4]
0
0
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain recorded by participants in an e-diary. Fever was defined as temperature: >=38.0 deg C, and categorized as: >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C, and >40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity, and severe: prevented daily routine activity. Vomiting graded as mild: 1 to 2 times in 24h, moderate: >2 times in 24h, severe: required intravenous hydration, and grade 4: ER visit or hospitalization for hypotensive shock. Diarrhea graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h, severe: 6 or more loose stools in 24h, and grade 4: ER visit or hospitalization for severe diarrhea. Exact 2-sided CI, based on Clopper and Pearson method used.
Query!
Timepoint [4]
0
0
Within 7 Days After Vaccination 2
Query!
Primary outcome [5]
0
0
Percentage of Participants With Adverse Events Within 1 Month After Vaccination 1
Query!
Assessment method [5]
0
0
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method.
Query!
Timepoint [5]
0
0
Within 1 month after Vaccination 1
Query!
Primary outcome [6]
0
0
Percentage of Participants With Adverse Events Within 1 Month After Vaccination 2
Query!
Assessment method [6]
0
0
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method.
Query!
Timepoint [6]
0
0
Within 1 month after Vaccination 2
Query!
Primary outcome [7]
0
0
Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 1
Query!
Assessment method [7]
0
0
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; or that was considered to be an important medical event.
Query!
Timepoint [7]
0
0
Within 1 Month After Vaccination 1
Query!
Primary outcome [8]
0
0
Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 2
Query!
Assessment method [8]
0
0
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; or that was considered to be an important medical event.
Query!
Timepoint [8]
0
0
Within 1 Month After Vaccination 2
Query!
Primary outcome [9]
0
0
Geometric Mean Ratio (GMR) Based on Geometric Mean Concentration (GMC) of Full-Length S-binding Immunoglobulin G (IgG) at 1 Month After BNT162b2 Vaccination
Query!
Assessment method [9]
0
0
GMCs of full-length S-binding IgG level for the coadministration group and separate administration group were reported in this outcome measure in descriptive data section. GMC and the 2-sided 95% CI were calculated by exponentiating the LSMeans of the concentrations and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of vaccine group, age group, and the corresponding baseline assay results (log scale). Assay results below the LLOQ were set to 0.5*LLOQ. Geometric mean ratio (GMR) was reported in the statistical analysis section and was calculated as ratio of GMCs in the coadministration group to the separate administration group. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure.
Query!
Timepoint [9]
0
0
1 Month After BNT162b2 vaccination
Query!
Primary outcome [10]
0
0
Geometric Mean Ratio (GMR) Based on Geometric Mean Titer (GMT) of Strain-Specific Hemagglutination Inhibition (HAI) at 1 Month After SIIV Vaccination
Query!
Assessment method [10]
0
0
GMTs of strain-specific HAI titers for the coadministration group and separate administration group were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the LSMeans of the titers and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of vaccine group, age group, and the corresponding baseline assay results (log scale). Assay results below the LLOQ were set to 0.5*LLOQ, and results above the ULOQ were set to ULOQ+1. Geometric mean ratio (GMR) was reported in the statistical analysis section and was calculated as ratio of GMT in the coadministration group to the separate administration group. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure.
Query!
Timepoint [10]
0
0
1 Month After SIIV vaccination
Query!
Secondary outcome [1]
0
0
Geometric Mean Concentration (GMC) of Full-Length S-binding IgG Levels Before Vaccination and 1 Month After BNT162b2 Vaccination
Query!
Assessment method [1]
0
0
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t-distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''.
Query!
Timepoint [1]
0
0
Before BNT162b2 vaccination, and 1 month After BNT162b2 vaccination
Query!
Secondary outcome [2]
0
0
Geometric Mean Fold Rise (GMFR) of Full-Length S-binding IgG Levels From Before Vaccination to 1 Month After BNT162b2 Vaccination
Query!
Assessment method [2]
0
0
GMFR was defined as ratio of the geometric mean concentration of IgG at 1 month after BNT162b2 vaccination to the geometric mean concentration of IgG before BNT162b2 vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''.
Query!
Timepoint [2]
0
0
From before BNT162b2 vaccination to 1 month After BNT162b2 vaccination
Query!
Secondary outcome [3]
0
0
Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Titers Before Vaccination and 1 Month After BNT162b2 Vaccination
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Before BNT162b2 vaccination, and 1 month after BNT162b2 vaccination
Query!
Secondary outcome [4]
0
0
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After BNT162b2 Vaccination
Query!
Assessment method [4]
0
0
SARS-CoV-2 neutralization assay (reference strain) (for a subset of approximately 200 participants).
Query!
Timepoint [4]
0
0
From before BNT162b2 vaccination to 1 month after BNT162b2 vaccination
Query!
Eligibility
Key inclusion criteria
1. Participants 18 through 64 years of age, inclusive, at the time of consent.
2. Are willing and able to comply with all scheduled visits, treatment plan, laboratory
tests, lifestyle considerations, and other study procedures.
3. Adults determined by clinical assessment, including medical history and clinical
judgment, to be eligible for the study, including adults with preexisting stable
disease, defined as disease not requiring significant change in therapy in the
previous 6 weeks or hospitalization for worsening disease within 12 weeks before
receipt of study intervention.
4. Have received 3 prior doses of 30 µg BNT162b2, with the third dose being at least 90
days before Visit 1 (Day 1). Documented confirmation of prior BNT162b2 receipt must be
obtained prior to randomization.
5. Capable of giving personal signed informed consent, which includes compliance with the
requirements and restrictions listed in the ICD and in this protocol.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
64
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Other medical or psychiatric condition, including recent (within the past year) or
active suicidal ideation/behavior, or laboratory abnormality that may increase the
risk of study participation or, in the investigator's judgment, make the participant
inappropriate for the study.
2. Allergy to egg proteins (egg or egg products) or chicken proteins.
3. History of Guillain-Barré syndrome.
4. History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the study intervention(s).
5. A positive SARS-CoV-2 test result (either by NAAT or rapid antigen test) within 28
days of Visit 1 (Day 1).
6. Immunocompromised individuals with known or suspected immunodeficiency, as determined
by history and/or laboratory/physical examination.
7. Bleeding diathesis or condition associated with prolonged bleeding that would, in the
opinion of the investigator, contraindicate intramuscular injection.
8. Women who are pregnant or breastfeeding.
9. Vaccination with any influenza vaccine <6 months before study intervention
administration, or planned receipt of any licensed or investigational nonstudy
influenza vaccine during study participation.
10. Individuals who receive treatment with radiotherapy or immunosuppressive therapy,
including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids
are administered for =14 days at a dose of =20 mg/day of prednisone or equivalent),
eg, for COPD, or planned receipt throughout the study. Inhaled/nebulized,
intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
11. Receipt of blood/plasma products or immunoglobulin, from 60 days before study
intervention administration or planned receipt throughout the study.
12. Receipt of any passive antibody therapy specific to COVID-19 from 90 days before study
intervention administration or planned receipt throughout the study.
13. Prior receipt of any COVID-19 vaccine other than BNT162b2 or receipt of more than 3
prior doses of BNT162b2.
14. Participation in other studies involving study intervention within 28 days prior to
study entry and/or during study participation.
15. Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct
of the study, site staff otherwise supervised by the investigator, and their
respective family members.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/04/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/10/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1134
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Northern Beaches Clinical Research - Brookvale
Query!
Recruitment hospital [2]
0
0
Australian Clinical Research Network - Sydney
Query!
Recruitment hospital [3]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [4]
0
0
Paratus Clinical Research Brisbane - Albion
Query!
Recruitment hospital [5]
0
0
AusTrials - Wellers Hill - Wellers Hill
Query!
Recruitment hospital [6]
0
0
Emeritus Research - Camberwell
Query!
Recruitment hospital [7]
0
0
Barwon Health - Geelong
Query!
Recruitment postcode(s) [1]
0
0
2100 - Brookvale
Query!
Recruitment postcode(s) [2]
0
0
NSW 2035 - Sydney
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
4010 - Albion
Query!
Recruitment postcode(s) [5]
0
0
4121 - Wellers Hill
Query!
Recruitment postcode(s) [6]
0
0
3124 - Camberwell
Query!
Recruitment postcode(s) [7]
0
0
3220 - Geelong
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Auckland
Query!
Country [2]
0
0
New Zealand
Query!
State/province [2]
0
0
BAY OF Plenty
Query!
Country [3]
0
0
New Zealand
Query!
State/province [3]
0
0
Canterbury
Query!
Country [4]
0
0
New Zealand
Query!
State/province [4]
0
0
Hawke's BAY
Query!
Country [5]
0
0
New Zealand
Query!
State/province [5]
0
0
Manawatu-wanganui
Query!
Country [6]
0
0
New Zealand
Query!
State/province [6]
0
0
Waikato
Query!
Country [7]
0
0
New Zealand
Query!
State/province [7]
0
0
Wellington
Query!
Country [8]
0
0
New Zealand
Query!
State/province [8]
0
0
Nelson
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
BioNTech SE
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Pfizer
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2
when coadministered with SIIV compared to separate administration of the vaccines when given
1 month apart (SIIV followed by BNT162b2), in participants who have received 3 prior doses of
30 µg BNT162b2, with the third dose being at least 90 days before Visit 1 (Day 1).
- Healthy adults 18 through 64 years of age will be randomized 1:1 to either the
co-administration group, or the separate administration group
- The duration of the study for each participant will be approximately 2 months
- There are 3 scheduled study visits each about 1 month apart
- The study will be conducted in New Zealand and Australia.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05310084
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05310084
Download to PDF